UNCYUnicycive Therapeutics Inc
UNCY
Unicycive Therapeutics Inc3,120
Mkt Cap
$175.91MVolume
309,327.0052W High
$11.0052W Low
$3.71PE Ratio
-3.45UNCY Fundamentals
Price
$6.90Prev Close
$6.97Open
$6.9750D MA
$6.67Beta
0.79Avg. Volume
456,861.01EPS (Annual)
-$1.67P/B
5.10Rev/Employee
$0.00$50.60
Equities Analysts Offer Predictions for UNCY Q1 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at Brookline Capital Markets issued their Q1 2026 earnings per share estimates for Unicycive Therapeutics in a research note issued on Tuesday, April 7th. Brookline Capital Markets analyst K. Raja expects that the company will post...
MarketBeat·6d ago
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Moderate Buy" by Brokerages
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assi...
MarketBeat·7d ago
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, April 9, 2026 NEW YORK, April 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire·7d ago
Brookline Capital Markets Estimates UNCY Q2 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Unicycive Therapeutics in a report issued on...
MarketBeat·7d ago
Benchmark Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $15.00
Benchmark lowered their target price on shares of Unicycive Therapeutics from $21.00 to $15.00 and set a "speculative buy" rating for the company in a research note on Monday...
MarketBeat·10d ago
HC Wainwright Issues Positive Estimate for UNCY Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at HC Wainwright increased their Q1 2026 EPS estimates for Unicycive Therapeutics in a note issued to investors on Tuesday, March 31st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post...
MarketBeat·13d ago
Guggenheim Has Lowered Expectations for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price
Guggenheim decreased their price target on Unicycive Therapeutics from $46.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday...
MarketBeat·14d ago
Noble Financial Has Positive Forecast for UNCY Q1 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Equities research analysts at Noble Financial increased their Q1 2026 earnings per share (EPS) estimates for shares of Unicycive...
MarketBeat·14d ago
UNCY Retail Buzz Explodes 150% This Week as Traders Bet Big on Experimental Drug Approval
UNCY has resubmitted its application seeking the U.S. Food and Drug Administration’s approval for Oxylanthanum carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.
Noble Financial Brokers Boost Earnings Estimates for UNCY
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Stock analysts at Noble Financial increased their Q3 2026 earnings per share estimates for Unicycive Therapeutics in a research report...
MarketBeat·15d ago
<
1
2
...
>